As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
Novartis AG ADR NVS
News
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
Novartis' Kisqali Reduces Breast Cancer Recurrence by Nearly One-Third, Trials Show
Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation
Novartis Gets Positive Test Results for Cholesterol Drug
Novartis Confirms Offer for Diagnostic Arm From Siemens Healthineers
Novartis says FDA gives accelerated approval for kidney-disease treatment
Novartis Says FDA Gives Accelerated Approval for Kidney-Disease Treatment
Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Novartis's Scemblix Granted FDA Priority Review
Trending: Novartis Raises Profit Guidance as It Prepares for Patent Expirations
Novartis lifts guidance again as demand climbs for top drugs
Novartis Raises Profit Guidance as Key Drugs Boost Sales — Update
Novartis Raises Profit Guidance as Key Drugs Boost Sales
Novartis On Pace for Record High Close — Data Talk
Novartis on Track for Record High Close — Data Talk
Carisma Therapeutics Notifies Novartis Pharmaceuticals of Terminated Manufacturing, Supply Agreement
United States